Your search results.

10 November 2012 Hepatitis C

Boehringer Ingelheim’s interferon-free all-oral hepatitis C treatment shows up to 85% viral cure in study including patients with advanced liver disease

• Size: 24 kB
• Last Update: 12.11.2012

12 November 2012 DARPin

Boehringer Ingelheim enters strategic collaboration agreement to support Molecular Partner’s proprietary pipeline with clinical supply of DARPin® molecules

• Size: 11 kB
• Last Update: 12.11.2012

13 November 2012_PreEMT

Boehringer Ingelheim and BaroFold Announce Strategic Agreement on PreEMT™ High Pressure Protein Refolding Technology

• Size: 9 kB
• Last Update: 13.11.2012

M270 WCPD Poster Portrait 900 x 1300:Layout 1

Hach T, Lambers Heerspink HJ, Pfarr E, Lund SS, Ley L, Broedl UC, Woerle HJ Phase II (1245.9,.10 pooled analysis; encore of EASD 2012) The sodium glucose cotransporter 2 (SGLT2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes

• Size: 177 kB
• Last Update: 6.11.2012

Molucular partners

• Size: 16 kB
• Last Update: 7.11.2012

Newshome

• Size: 4 kB
• Last Update: 8.11.2012

USA flag

• Size: 1 kB
• Last Update: 29.10.2012

USA flag small

• Size: 1 kB
• Last Update: 29.10.2012

idf_qrcode_hach.pdf

Joint 9th International Diabetes Federation Western Pacific Region (IDF-WPR) Congress and 4th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD), 24-27 November 2012, Kyoto, Japan Hach T, Lambers Heerspink HJ, Pfarr E, Lund SS, Ley L, Broedl UC, Woerle HJ Phase II (1245.

• Size: 44 kB
• Last Update: 29.10.2012